Evidence map›Paper›PMID 42271184›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Cognitive status moderates long-term benefits of non-pharmacological insomnia therapy in older adults: A secondary analysis of a randomized clinical trial.

Kathleen P O'Hora, Allison B Morehouse, Beatriz Hernandez, Kristen F Burda, Madeline C Babros, Laura Lazzeroni, Jamie M Zeitzer, Leah Friedman, Donn Posner, Clete Kushida and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02117388 (Treatments for Insomnia), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02117388 nacompletednot on this map

Treatments for Insomnia: Mediators, Moderators and Quality of Life

TypeinterventionalSponsorPalo Alto Veterans Institute for ResearchRan2013 to 2019Enrolled128ConditionsInsomniaArmsSleep Restriction, Cognitive Behavioral Therapy, Combined Therapy
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kathleen P O'HoraDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Allison B MorehouseDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Beatriz HernandezDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Kristen F BurdaDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Madeline C BabrosDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Laura LazzeroniDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Jamie M ZeitzerDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Leah FriedmanMental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, California, Palo Alto, USA.
Donn PosnerDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Clete KushidaDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Rachel ManberDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Jerome A YesavageDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.
Andrea N Goldstein-PiekarskiDepartment of Psychiatry and Behavioral Sciences, Stanford University, California, Stanford, USA.

Funding

The Mental Illness Research Education and Clinical Center at Veterans Affairs Palo Alto Health Care SystemThe National Institute of Mental Health NIMHR01MH101468
6 · The paper itself

Abstract

introductionThis secondary analysis examined whether mild cognitive impairment (MCI) moderates the effectiveness of non-pharmacological insomnia therapy and whether insomnia therapy is associated with clinically meaningful symptom reduction.

methodsCognitively intact (CI; n = 87) and MCI (n = 38) older adults with insomnia completed insomnia therapy. The primary outcome was the Insomnia Severity Index (ISI), assessed at baseline, post-treatment, and 6-month follow-up (6FU). Linear mixed effects models evaluated ISI changes across time and group. Logistic regression examined clinically meaningful reductions (ISI decrease ≥ 6).

resultsBoth groups showed significant ISI reductions at post-treatment and 6FU (p-values < 0.0001). There were no between-group differences at post-treatment (p = 0.869). Yet, at 6FU, CI participants, compared to MCI, showed significantly greater symptom reduction (p = 0.036), and a higher proportion achieved clinically meaningful reduction in ISI (78.7% vs. 45.8%). DISCUSSION: Older adults with MCI benefit from insomnia therapy; however, their continued symptom reduction 6-months later may be dampened compared to CI older adults. CLINICAL TRIAL REGISTRATION INFORMATION: Treatments for Insomnia: Mediators, Moderators and Quality of Life ClinicalTrials.gov, NCT02117388.

Indexed as

CognitionCognitive DysfunctionSleep Initiation and Maintenance DisordersAgedAged, 80 and overFemaleHumansMaleNeuropsychological TestsSeverity of Illness IndexTreatment OutcomecognitionCognitive Behavioral Therapy for Insomniadaily functioninginsomniamild cognitive impairmentmoodolder adults

Identifiers

PMID42271184
PMCPMC13253365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.